Free Essay

The Fda

In: Other Topics

Submitted By jldgibbs73
Words 3299
Pages 14
One of the oldest U.S. consumer protection agencies, the Food and Drug Administration (FDA) protects the public from unsafe foods, drugs, medical devices, cosmetics, and other potential hazards. As part of the department of health and human services, the FDA annually regulates over $1 trillion worth of products, which account for one-fourth of all consumer spending in the United States. It also protects the rights and safety of patients in clinical trials of new medical products, monitors the promotional activities of drug and device manufacturers, regulates the labeling of all packaged foods, and monitors the safety of the nation's blood supply.

To ensure compliance with its regulations, the FDA employs over 1,000 investigators and inspectors who visit over 15,000 food-processing, drug-manufacturing, and other facilities each year. If it finds violations of law, the FDA first encourages an offending company to voluntarily correct the problem or to recall a faulty product from the market. If the firm does not voluntarily comply with the law, the FDA may take it to court and seek criminal penalties against it. The FDA may also seize faulty products, order product recalls, seek injunctive relief, impose fines, and take other types of enforcement action. Each year, the FDA declares about 3,000 products and 30,000 import shipments to be unacceptable in various ways.

The FDA employs over 2,000 scientists—including 900 chemists and 300 microbiologists—who provide the scientific evidence to back up its regulatory and inspection duties. These scientists analyze samples of products for purity and review test results of new products. The FDA itself does not do research for a new medical product. Instead, it evaluates the results of studies undertaken by the manufacturer.


Food production in the United States has been regulated since the late eighteenth century. Colonies and, later, states passed laws banning impurities from selected foods. In 1848, the United States began regulating imported drugs, under the Drug Importation Act (Ch. LXX, 9 Stat. 237). The enforcement of food and drug laws was first assigned to the Chemical Division of the new u.s. department of agriculture (USDA) in 1862 (12 Stat. 387).

The need for laws to regulate food and drug purity became increasingly urgent in the late nineteenth century, when substances such as opium, cocaine, and heroin were commonly added to medicinal elixirs and tonics. The need for government regulation was also made evident in Upton Sinclair's book, The Jungle, which exposed the unsanitary conditions of Chicago's meatpacking industry and shocked the nation. On June 30, 1906, Congress, with the support of President theodore roosevelt, passed two landmark pieces of Progressive Era legislation that strengthened the government's ability to protect consumers: the Food and Drug Act (34 Stat. 768 [21 U.S.C.A. § 1–15]) and the Meat Inspection Act (21 U.S.C.A. § 601 et seq.). The former prohibited interstate commerce in misbranded and adulterated foods, drinks, and drugs, and the latter addressed the unsanitary conditions and use of poisonous preservatives and dyes in the meatpacking industry.

In 1927, Congress authorized the creation of the Food, Drug, and Insecticide Administration within the U.S. Department of Agriculture. In 1930, the agency's name was changed to the current one, Food and Drug Administration (Agriculture Appropriation Act, 46 Stat. 976).

In 1937, 107 people died after taking the elixir sulfanilamide, a supposedly healing tonic. This tragedy prompted the passage of the next major reform of food and drug law, the Federal Food, Drug, and Cosmetic Act of 1938 (21U.S.C.A. § 301 et seq.). The FDA was then entrusted with the regulation of cosmetics and therapeutic devices and was authorized to do factory inspections. Even more importantly, the act required new drugs to be tested on animals and humans for safety before being marketed. In 1957, the Food Additives Amendment (Pub. L. 85-250, Aug. 31, 1957, Stat. 567) required the evaluation of food additives to establish safety, and in the following year, the Delaney Clause (Pub. L. 85-929, Sept. 6, 1958, 72 Stat. 1784) forbade the use in food of substances found to cause cancer in laboratory animals.

How the FDA Approves New Drugs

The process by which the Food and Drug Administration (FDA) approves drugs as safe and effective is generally long and complicated, though it may vary according to the type of drug and the nature of the illness for which it is being developed. The FDA refers to drugs under development as investigational new drugs, or INDs.

The evaluation of new drugs requires the skills of many different FDA scientists and professionals performing a wide variety of tasks. Biochemists and molecular biologists evaluate the basic chemistry and biology of new chemical compounds and molecular structures. Toxicologists assess the potential harm of proposed drugs, and pharmacologists study how these drugs affect the body and are broken down and absorbed by it. Computer scientists create electronic models that aid in the understanding of new chemicals. Physicians evaluate the results of clinical trials, assessing both the beneficial and adverse effects of the drugs. And statisticians evaluate the design and results of controlled studies.

It is an expensive and time consuming process, particularly for the company developing the drug, called a drug sponsor. A sponsor spends an average of $359 million for each new drug brought to market. Typically, the process takes eight and a half years and may be divided into roughly three stages: preclinical trials, involving animal and other laboratory tests (lasting one and a half years on average); clinical trials, involving tests on humans (five years); and FDA review (two years).

Preclinical Trials Once a sponsor has developed a drug, it must test the drug on animals in the laboratory. In doing so, the drug sponsor must follow FDA guidelines and regulations. These tests, also called preclinical trials, are usually done on more than one species of animals. FDA guidelines call for the inspection of animal laboratories every two years to ensure that they are being operated according to the administration's regulations.

After short-term lab testing has been performed and the sponsor has deemed its results adequate, the sponsor submits test data and plans for future clinical trials to the FDA. FDA scientists, together with a local institutional review board composed of scientists, ethicists, and nonscientists, then conduct a thirty-day safety review to decide whether to allow testing on humans. The vast majority of new drugs tested in the laboratory are rejected by either the sponsor or the FDA because they are unsafe or ineffective.

If the FDA indicates approval, the drug sponsor may begin clinical testing on humans. Even if a drug is approved for clinical trials, the sponsor continues animal testing of the drug in order to better understand the drug's long-term effects.

Clinical Trials Clinical trials are scientifically controlled studies in which the drug being tested is given to one group of patients, while another treatment, often a placebo (an inactive substance that looks like the drug being tested), is given to another group. Ideally, neither group of patients knows which is receiving the new drug and which is receiving the placebo.

The clinical trials, like the animal tests, examine what happens to the drug in the body, including whether it is changed, or metabolized, in the body, how much of it is absorbed into the blood, and how long it remains in the body. If human tests produce unexpected results, researchers may conduct further animal tests to better understand the drug.

Clinical trials proceed in three phases: Phase 1 involves testing primarily for safety and dosage level. Twenty to one hundred healthy patients are assessed over several months. If the results are within FDA safety guidelines, the trials proceed to phase 2.

Phase 2 involves a greater number of patients—up to several hundred—who have the condition that the drug is intended to treat. During this stage, which lasts from several months to two years, researchers attempt to determine the drug's effectiveness in achieving its stated purpose, as well as its safety. At the end of this phase, sponsors meet with FDA officials to discuss the best way to conduct the next phase of testing.

In phase 3, the most crucial stage of testing, the number of patients is expanded still further, to several hundred to several thousand, and the length of the study is increased to one to four years. This phase establishes the correct dosage of the drug and how it will be labeled, and provides further evidence regarding its safety and effectiveness.

Of one hundred drugs submitted for testing in humans, an average of seventy will pass phase 1. Of these seventy, on average, only thirty-three will remain after phase 2 testing, and twenty-five to thirty after phase 3. Finally, an average of only twenty will actually receive FDA approval.

Once the drug sponsor has completed clinical trials, it submits a new drug application (NDA) to the FDA, requesting approval to market the drug. This application consists of documentation detailing the chemical composition of the drug, the design of the trials, the results of the trials, and the means by which the drug is made and packaged.

FDA Review In assessing an NDA, the FDA undertakes its closest scrutiny of all during the drug approval process. Its principal goal during review is to determine whether the benefits of the new drug outweigh the risks. To reach this determination, the FDA examines the documentation provided by the sponsor and looks at samples of the drug.

If inadequacies are discovered in the NDA, the FDA may require additional information, further testing, or modified labeling. In cases where it is difficult to establish clearly whether the benefits of the drug outweigh the risks, a panel of outside experts is often consulted.

If the FDA approves the drug, the sponsor may begin manufacturing and marketing the drug immediately.

The FDA does not stop monitoring a drug once it has been marketed. It continues to evaluate the drug's safety and effectiveness through its program of postmarket surveillance. This program consists of surveys, the testing of product samples, and the analysis of reported adverse reactions.

Speeding Drugs to Those Who Need Them The FDA has longstanding policies allowing what it calls the compassionate use of new drugs for those in desperate need. Innovative cancer treatments, for example, have been made available to patients since the 1970s through the National Cancer Institute.

However, during the 1980s, the FDA came under increasing fire for its slow approval of new drugs. Particularly with the emergence of AIDS during the 1980s, the public outcry for fast delivery of innovative new drugs strengthened. As science produces ever more pharmaceuticals, the FDA is called on to review drug applications as quickly as is reasonably possible.

In response to the growing demand for speedy drug evaluation, the FDA has made significant changes in its review protocols. In 1987, for example, the agency adopted "expanded access" regulations, which permit certain drugs to be designated as treatment INDs. A treatment IND may be administered to patients even while it is still undergoing clinical trials. This program allows patients with no other alternatives to undergo a treatment that may benefit their health. By August 1994, twenty-nine agents had been designated treatment INDs, and by 1995, more than seventy-five thousand patients had received access to new therapies through this program. New drugs used to treat patients with AIDS are made available through a similar process known as the parallel track approach.

Identifying priorities is another method the FDA uses to provide more rapid access to promising new treatments. AIDS drugs, drugs that treat life-threatening or severely debilitating illnesses, and drugs that appear to offer significant improvements over existing therapies are classified as priority drugs and receive faster review than those classified as standard drugs. With priority drugs, the FDA typically becomes involved earlier in the development process, and is thereby able to more quickly review the relevant applications.

Drugs are also classified as to chemical type, so that those closely similar in structure to existing drugs will receive less intensive review than those with a molecular structure that has never been marketed before.

Accelerated approval is another mechanism for faster review of promising new drugs. Under this program, created in 1991, a product may be approved for limited use if it has been shown in trials to achieve particular results—such as lowering blood pressure or cholesterol. Drugs approved under this program include didanosine for AIDS, interferon beta-1B for multiple sclerosis, and DNase for cystic fibrosis.

The Prescription Drug User Fee Act of 1992 (Pub. L. 102-571, Title 1, Oct. 29, 1992, 106 Stat. 4491 to 4500) has also enabled the FDA to speed drug review. Under this law, fees paid by drug manufacturers are used by the agency to hire hundreds of additional review staff and buy improved equipment, including computers that make review more efficient.

The FDA is also attempting to streamline red tape and bureaucracy. In 1995, President bill clinton and Vice President albert gore, Jr., announced that twenty-one separate product license applications used by the FDA would be consolidated into one simplified form. This form would also be available in an electronic format, making it easier to distribute, prepare, and review.

Results indicate that these changes have led to faster approval of important new drugs. One signal success of FDA reform was the prompt approval of taxol, a treatment for advanced ovarian cancer that was approved in December 1992 after a record 5 months. By 1994, all new drugs were being approved by the FDA in a median time of 19 months, and priority drugs with important therapeutic uses were approved in an average of 10.4 months. In the late 1980s, by comparison, the FDA took an average of 27 months to approve new drugs.

In 1995, President Clinton established even more ambitious new goals for FDA approval. These goals, to be met by 1997, require the FDA to approve priority drugs within 6 months and standard drugs within 12 months.

In 1962, the Kefauver-Harris Drug Amendments (Pub. L. 87-781, Oct. 10, 1962, 76 Stat.780) were passed. These laws required drug manufacturers not only to show that their drugs were safe but also to prove that their drugs achieved the effects claimed. That same year, FDA regulations were shown to be effective after the drug thalidomide, for which the FDA had delayed approval, caused thousands of birth defects in western Europe.

In 1979, the FDA was made part of the Department of Health and Human Services (96 Stat. 668, 695). Other laws with major implications for the FDA's activities include the 1990 Nutrition Labeling and Education Act (Pub. L. 101-535, Nov. 8, 1990, 104 Stat. 2353), which requires all packaged foods to carry labels with nutrition information, and the Prescription Drug User Fee Act of 1992 (Pub. L. 102-571, Title 1, Oct. 29, 1992, 106 Stat. 4491 to 4500), which requires drug and biologics manufacturers to pay fees that support FDA assessment of their products.

Effective October 2002, the FDA implemented its National Organic Program (NOP) under the Organic Foods Production Act of 1990 (OFPA), 7 U.S.C. 6501 et. seq. The NOP sets the first national standards for the use of the label term organic on food items and products. Products that qualify as "100 percent organic" under NOP rules may use the "USDA Organic" seal on their principal display panel. The rules specifically prohibit the use of genetic engineering methods, ionizing radiation (irradiation), and sewage sludge for fertilization. In addition, all agricultural products that are labeled organic must originate from farms or handling operations that have been certified by a state or private agency accredited by the USDA.


The FDA carries out its activities through a number of subdivisions. The Center for Drug Evaluation and Research regulates the safety, effectiveness, and labeling of all prescription and over-the-counter drugs intended for human use. It also monitors drug advertising for accuracy, ensures the safety and rights of patients in drug studies, and distributes information on drug products to the medical community and the public.

The Center for Biologics Evaluation and Research regulates biological products, which include blood, vaccines, human tissues, and drugs derived from living organisms. It coordinates an AIDS program, which works to develop an AIDS vaccine and AIDS diagnostic tests. It also conducts research on the safety of blood and blood products and inspects manufacturing plants to ensure compliance with FDA standards.

The Center for Food Safety and Applied Nutrition develops regulations related to food, food additives and colorings, and cosmetics. The Center for Devices and Radiological Health seeks to ensure the safe use of potentially hazardous radiation such as that produced by X rays. It conducts research into the effects of exposure to radiation-producing medical devices and develops manufacturing standards for such devices.

The Center for Veterinary Medicine evaluates the safety of drugs and devices used on animals. The National Center for Toxicological Research assesses the biological effects of toxic chemical substances.

AZT: An Agent of Change for the FDA

Azidothymidine (AZT) is a celebrated example of speedy FDA approval of a new drug. The unusually swift approval of AZT during the early years of the AIDS (acquired immune deficiency syndrome) epidemic led to the creation of a new FDA category, treatment investigational new drug (treatment IND), that established new procedures for more rapid and flexible drug approval.

The pharmaceutical company Burroughs Wellcome first presented AZT as a new drug to the FDA in June 1985. Public fear of AIDS had increased dramatically during the previous few years, as had protests by AIDS activists who complained of slow FDA movement with regard to promising new treatments. Keenly aware of the need for swift decision making in the face of the deadly AIDS disease, the FDA approved phase 1 clinical trials of the drug within one week of the initial application.

Phase 1 testing of AZT, between July and December 1985, was promising, and phase 2, involving 300 patients in placebo-controlled trials, began in February 1986. After six months, 19 of the 137 patients in the group taking the placebo had died, whereas only 1 of 145 in the group taking AZT had died. The results were encouraging enough for the FDA to forgo further testing. The group taking the placebo was switched to AZT, and phase 3 testing, traditionally the most important step in clinical trials, was deemed unnecessary.

In September 1986, the FDA authorized the treatment of patients who wanted access to AZT, even before it had given approval to the drug. By the time approval for general public use came in March 1987, some 4,000 patients had already been treated with AZT, and thus the drug was already potentially extending the lives of hundreds of people.

Taking an example from its handling of AZT, the FDA in May 1987 created the treatment IND classification to facilitate faster approval and wider distribution of promising new therapies for life-threatening diseases. The rapid approval of AZT also proved greatly encouraging to the pharmaceutical industry, which could now hope to bring AIDS drugs to market much more rapidly and at lower cost.

Acquired Immune Deficiency Syndrome.

Other offices of the FDA include the Office of Policy, the Office of External Affairs, the Office of Management and Systems, the Office of AIDS Coordination, the Office of Orphan Products Development, and the Office of Biotechnology. The administration operates six field offices, 21 district offices, and 135 resident inspection posts throughout the United States and Puerto Rico.

"Food and Drug Administration." West's Encyclopedia of American Law. 2005. 30 Apr. 2016 .

Similar Documents

Premium Essay


...The use of senses in understanding the view of the world is one of the most infant ways to view the world. The way a person speaks can tell a lot about the intention, and the feeling that a person has when speaking. Also the look of the way the environment is can make a person assume a specific way about the area. The way something smells can make a person decide, without any other information, whether or not they like a product or service. The way the senses guide people in their decision making can either make them have conscious decisions or it can make them close-minded to the area around them. The three main functions of sensory information are: The sensory nerves gather information from the environment then sends that info to the spinal cord, which then speed the message to the brain. The brain then makes sense of that message and fires off a response. Motor neurons deliver the instructions from the brain to the rest of your body. The spinal cord, made of a bundle of nerves running up and down the spine, is similar to a superhighway, speeding messages to and from the brain at every second (The Brain, 2005). Information is passed from the sensory memory into short-term memory via the process of attention (the cognitive process of selectively concentrating on one aspect of the environment while ignoring other things), which effectively filters the stimuli to only those which are of interest at any given time (Sensory Memory). Sensory memory is an ultra-short-term......

Words: 834 - Pages: 4

Premium Essay


...Dfssdsdfa Dfas Dfas Dfs Afd Sf Sdafsd Afsd Afsd Afsd Afsda Sd F Se Fsrfse Rtrlfk kk k rk rk rer ll l l rlel l osos oll lrwl Fkskfk s Kfskfk Kkfskfs S S kfkkrsoroes Fklslala Kedkeak Askfkosao Keklalelaeo Eoaoe Dosaa e supply chain and headed Zara in Scandinavia. “Martinez will use his experience in supply-chain management to improve the delivery time-lag at Esprit,” said Paul Cheng, vice chairman of Esprit. “We used to launch new products every season, but now we may need to move quicker.” In June, Inditex reported a 30 percent gain in first- quarter profit, beating analyst estimates. The retailer’s success is reflected in the rising fortune of Amancio Ortega, its septuagenarian founder who this week bumped Warren Buffett from his perch as the world’s third-richest person. The 76-year- old Spanish tycoon’s fortune climbed by $1.6 billion to $46.6 billion on Aug. 6, according to theBloomberg Billionaires Index, as Inditex stock rose to a record. Fashion Pioneer Esprit’s revenue growth slowed to 0.1 percent in the year ended June, from 26 percent in 2008, according to data compiled by Bloomberg. Inditex’s sales increased 10 percent in the year ended January, topping H&M’s 1.4 percent gain for the year to November and Gap’s 0.8 percent drop in the year ended January. Zara, the main Inditex brand, was a pioneer of fast-fashion and has sought to reproduce designer looks at affordable price. “It is certainly a blow to Inditex to lose one...

Words: 470 - Pages: 2

Premium Essay

Fda Approvals

...Agency for pharmaceuticals is a complex and often lengthy one. Done out of necessity to ensure the products being introduced into the growing healthcare field are overall safe and effective for utilization by patients. While the process is far from perfect it still a staple in introducing innovative and breakthrough drugs into healthcare fields across the board. This paper will discuss the process encountered to get pharmaceuticals approved for manufacture and distribution to physicians and patients. Food and Drug Agency’s Drug Approval Process “For healthcare technology, the most important regulatory approval comes from the federal Food and Drug Administration (FDA)” (Williams & Torrens, 2008, pg.28). This agency approves all drugs and pharmaceuticals, medical devices, and some medical equipment. The FDA also controls access to drugs by deciding whether a certain drug will be available by prescription only or as an over-the-counter purchase (Shi & Singh, 2013, pg.115). The most well-known regulatory review of medical technology is that conducted on pharmaceutical products and to some medical devices that are subjected to detailed preliminary approvals, clinical trials, and post-approval surveillance policies. Before a drug can begin (first phase) clinical testing, the sponsor of the drug must evaluate the product’s safety and biological activity via in vitro and in vivo lab (animal) testing. If product appears to have important biological activity and may be......

Words: 911 - Pages: 4

Premium Essay

Fda Proposals

...foods, will factor into my eating habits for myself and my family. This will affect me directly as it could lead to a change in the foods I choose to cook and eat. 2. Describe the proposal/change.  The proposal will allow the FDA to collect information from a study about the relationship between selenium and the risk of various cancers. The proposal will also dig deeper into scientific evidence of whether health claims are ‘complete, truthful and not misleading’. The proposal will enforce companies to enable the public to comprehend the information provided and to understand the relative significance of such information in the context of a total daily diet. 3. Write the public comment which you would submit to this proposal. If the proposed regulation deadline has already passed, write the comment you would have submitted. Explain briefly what you wish to accomplish with your comment. (10 points) My comment is that I encourage this new scientific study to be done so that the public is not misled on whether or not Selenium (trace mineral that is essential to good health but required only in small amounts) is beneficial to the body or not. There have been several claims that conclude that the mineral reduces the risk of certain cancers, but the FDA has ruled that these claims are very limited and not conclusive. For this reason, more research should be conducted. This new proposal will lead to the truth behind the alleged claims. I wish to have them carry-out this......

Words: 645 - Pages: 3

Free Essay

Memo Fda

...this chain of event FDA is also being dragged since FDA did not pass the Original Tracking Bar rule. A lot of people are saying that FDA is responsible for these, although it is clear that FDA does not have any liability towards the these victims. Robins and Robins has caused this problem and they were one of the most active members who opposed this regulation and even bribed companies to be against it. they went ahead and they convinced the addicts to support them. Robins and Robins lobbied against this rule and got the rule stopped during the public comments period. Even after Robins and Robins was aware of the problem caused by their medicine they did not make a justified effort to recall their product. It could never be a 100% recall since there is no tracking methodology that can be used. As far as the role played by FDA is concerned they did the right thing in stopping this bar code rule. They could not pass it without public’s consent and majority of them had voted against it. They thought it would violate their privacy rights. And also doing this would have increased the price of the medicine which was a big concern. As it is hard for people to afford medication as is and with this the price increase would have been tremendous. It was not only Robins and robins that lobbied against it but there were certain public interest groups involved as well. The death and illness have been caused because of the negligence of Robins and Robins and not the FDA. In response......

Words: 523 - Pages: 3

Premium Essay

Fda Policies

...U.S. Food and Drug Administration (FDA) drug review bears a structural similarity to many decisions made by other regulatory agencies: high uncertainty, low reversibility, avoidance of observable error, and high political stakes that induce lobbying by interested parties. This project explores the policy lessons to be learned from viewing FDA drug review as a politically shaped exercise in information processing. I argue that the incentives facing regulators induce limits on the degree to which drug review can be accelerated, that the same incentives could render privatization initiatives problematic, and that political pressures could play a useful role in identifying priority drugs. Patients, more than pharmaceutical firms, shape the political costs to the FDA of delaying drug approval. Consider two hypothetical consumers, one a pharmaceutical consumer (“patient”) who wishes to try a new drug for some ailment, the other a vitamin consumer who wishes to take zinc supplements to ward off a cold or flu. There are few institutional restrictions upon the consumption decisions of the vitamin consumer, at least in the United States. She is free to purchase vitamin products over the counter, and the vitamin manufacturer is free to sell them without prior authorization or licensing. Not so with pharmaceuticals. The marketplace for pharmaceuticals is one of the most highly regulated industries in the U.S. economy.1 To use any new pharmaceutical product, the patient must secure......

Words: 5125 - Pages: 21

Premium Essay


... 2. Describe the proposal/change. The Internal Revenue Service (IRS) issued proposed regulations that add excise tax on the sale of medical devices under Internal Revenue Code. The tax applies to the sale of certain medical devices by a manufacturer, producer or importer of the device. The tax is in the amount of 2.3 percent of the sale price and will apply to all devices that are sold after Dec. 31, 2012. The Treasury will be holding a public hearing on May 16, 2012, at the Internal Revenue Service in Washington, D.C., and comments on the proposed regulations and outlines of the topics to be discussed at the public hearing are due by May 7, 2012. The imposed sales tax will use the FDA Medical Device Listing for medical device categorization, and definition, such devices defined under this FDA regulatory law as “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or similar or related article, including any component, part, or accessory, which is recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, intended for use in the diagnosis of disease or other conditions, or the cure, mitigation, treatment, or prevention of disease, in man or animals, or intended to affect the structure or function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon......

Words: 1092 - Pages: 5

Free Essay

Core Functions of Fda

...Thesis: One of the biggest agencies within the U.S. Department of Health and Human Services is the Food and Drug Administration (FDA). The Office of the Commissioner and four directorates administer the core functions of the agency which are medical products and tobacco, foods and veterinary medicine, global regulatory operations and policy, and operations. While being a huge, big named agency designed to protect and provide public health; there are necessary regulations and guidelines to ensure the purpose of the agency is being met. This paper will explore the needs, stakeholders, expected outcomes, and other regulatory action and implementation of the FDA. Introduction: The Food and Drug Administration Safety and Innovation Act (FDASIA) is a regulation which was proposed by The Food and Drug Administration (FDA or Agency) to establish a list of “qualifying pathogens” that are likely to cause serious harm to public health. FDASIA utilizes the agency’s ability to protect and improve public health by giving the authority to collect user fees, promoting innovation, increasing stakeholder involvement, and enhancing the safety of the drug supply chain. Methicillin-Resistant Staphylococcus aureus (MRSA) is a “staph” germ that does not improve with the first-line antibiotics that typically cure staph infections. When this takes place, the germ is “resistant” to the antibiotic. This class of antibiotics includes penicillin, amoxicillin, oxacillin, methicillin, and others. (MRSA...

Words: 2680 - Pages: 11

Premium Essay

Fda to Regulate Drugs

...Mohammed’s part: What does the FDA do? FDA is responsible for protecting the public health by assuring the safety and security of human and veterinary drugs, biological products, and medical devices. FDA is also responsible for advancing the public health by helping to speed innovations that make medicines more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medicines to maintain and improve their health. Finally, FDA plays a significant role in the Nation’s counterterrorism capability. FDA fulfills this responsibility by fostering development of medical products to respond to deliberate and naturally emerging public health threats. What does the FDA regulate? The scope of FDA’s regulatory authority is very broad. FDA's responsibilities are closely related to those of several other government agencies. Often frustrating and confusing for consumers is determining the appropriate regulatory agency to contact. The following is a list of traditionally-recognized product categories that fall under FDA’s regulatory jurisdiction Drugs, including: • prescription drugs (both brand-name and generic) • non-prescription (over-the-counter) drugs • vaccines • blood and blood products • cellular and gene therapy products • tissue and tissue products The Federal Drug Act is the basic food and drug law of the U.S. With numerous amendments, it is the most extensive law of its kind in the world. ...

Words: 1260 - Pages: 6

Premium Essay

Fda Research Prospectus

...Food &Drug Administration (FDA) IT Security Project Plan ITEC640-9043 October 14, 2015 Table of Contents Introduction…………. …………………………………………………………………Page 3-4 Project Organization…………………….……………………………………………....Page 5-6 Statement of Need ………………………………………………………..…………….Page 7-8 Project Definition ………………………………………………………………………Page 8-10 Approach to Developing Project Plan………………………………………………….Page 11-12 References………………………………………………………………………………Page 13 Introduction Green Team Consulting Company is a team of professional project managers, who are hired to assist organizations with known network integrity issues after a cyber attack or data breach. The Greet Team is an investigative firm that specializes in a high quality, detailed analysis of the breach, development of a project mitigation plan, evaluation of any legal implications that may result in the future, and implementation strategies of new systems and workflows that will ensure future network security. Walter Harris, the Chief Operations Officer of the Food and Drug Administration or FDA, has contracted with the Green Team after a critical data breach that exposed confidential information. The data that was exposed includes but is not limited to: employee records, new pharmaceutical drug proposals, clinical trial results, and complaints filed about products the FDA regulates. The three main goals of this project will be to target the cause of the data breach, review the consequences this......

Words: 2776 - Pages: 12

Premium Essay

Corruption at the Fda and Epa

...Corruption in the FDA and USDA Scott A. Weidner Cardinal Stritch University Business Ethics MGT 460 Rozine Smith February 28, 2013 Table of Contents Abstract.............................................Page 3 Authors intent (thesis statement)....................Page 4 Ethical Concerns …………………………………………………………………………………………..Page 4 The Root of the Problem…………………………………………………………………………..Page 6 Chart of Monsanto appointees……………………………………………………………..Page 6 Which Administrations are Guilty…………………………………………………..Page 8 Obama Appointees……………………………………………………………………………………………..Page 10 Damage and Effects………………………………………………………………………………………….Page 12 Recommendations………………………………………………………………………………………………..Page 13 Abstract At the heart of the issues of corruption in the FDA and USDA are the appointees to the departments. Many are former employees of Monsanto. A former director of Monsanto made the statement Monsanto should not have to vouchsafe the safety of biotech food that is the job of the FDA. The FDA says that food manufactures should be responsible for what they produce. Ironically, the FDA is controlled largely by Monsanto, and Monsanto is regulated by the United States Government, with neither side willing to take ownership of the issue. The first Monsanto appointees in the FDA were placed under the first Bush administration. In each subsequent administration more appointees were taken from Monsanto. President Obama is responsible for the largest......

Words: 2340 - Pages: 10

Premium Essay

Fda Roles of Safety for the Public

...The Roles of the FDA in Protecting the Patient Rasmussen College Author Note This paper is being submitted on October 18, 2015, for Trang Nygyen’s PTN1009 Foundations of pharmacy practice. The FDA Roles in Protecting the Patient The current role of the FDA is to protect the public health by assuring the safety, efficacy and security of human and veternariny drugs, biological products, medical devices, our national food supply, cosmetics, and products that emit radiation.(“FDA Fundamentals, 2015”) The FDA serves as a consumer watchdog, making sure that medications are safe and effective to help improve patient’s health. All new drugs are evaluated before they can be sold to ensure they work correctly and the health benefits outweigh known risks. FDA monitors and ensures safety of drugs after approval. (“What is the FDA’s role in drug safety”, 2010-2015) Risk Evaluation and Mitigation Strategy (REMS) is used to manage a known or potential serious risk associated with a drug or biological product. REMS are required by the FDA if determined they are necessary. REMS include Medwatch, medication guide, and black labeling.(“REMS resource center, 2015”) Medwatch is an FDA safety information and adverse event reporting program. The FDA uses REMS by communicating safety information by releasing Medwatch safety alerts to subscribers and through the Medwatch partner program. The FDA posts monthly label changes on the web and distributes......

Words: 530 - Pages: 3

Premium Essay

Fda Approvals for Medical Trials

...Research Paper FDA Approval process for Clinical Trials If you, or someone you loved, were diagnosed with a terminal disease, would you chance using a non-FDA approved medication to increase your life expectancy? Many pharmaceutical companies have the medication that could save countless lives, but the FDA clinical trials for these medicines are problematic for enrollment, and thousands of patients are often turned down. New drugs are vitally important to improving the lives and health of Americans. Between 1986 and 2000, new drugs were responsible for 40 percent of the total increase in life expectancy. Yet, the FDA’s clinical trial process remains lengthy and expensive. It takes, on average, more than a decade to bring a new drug from the laboratory to the market. Polls show a clear majority of specialists believe the FDA clinical trial process is too slow and most report having been personally hindered in treating a patient due to the FDA approval process. The clinical trial process initiates when a drug developer submits an Investigational New Drug Application (IND) to the FDA. The IND application includes all available data on the proposed investigational drug, including the results of any animal testing. In reviewing IND applications, the FDA seeks to ensure that the proposed trial does not expose patients to “unreasonable risk of harm.” Clinical trials then move ahead in three mandatory human testing phases. Phase I consists of giving the investigational drug...

Words: 2316 - Pages: 10

Premium Essay

Fda Standards on Anti-Depressant

...Anti-Depressant Drugs and FDA Approval Anti-Depressant Drugs and FDA Approval Procedure Ashley Jensen A01054823 Pima Community College Psych 101 Abstract Antidepressant drugs fall under three main categories; MOAI’s, Tricyclic Antidepressants, and SSRI’s. Like any drug, Antidepressant drugs must get FDA approval prior to putting in on the market for society, ensuring it has no harmful effects. The Food and Drug Association has a series of trials, tests, and procedures, to ensure these drugs are safe and effective for people with severe depression. Effects of each Type of Antidepressant Drugs Anti-Depression drugs target the amygdala by directly by increasing the activity in the prefrontal cortex, therefore decreasing the reactivity in the amygdala. The amygdala has cortical and subcortical projection to other regions of the brain, such as the hippocampus, which is where we create and maintain memories. With the cortical projections increasing the level of activity for the amygdala, there is a possibility your brain will adapt and sustain a repetitive negative associations when approached with an emotion. Anti-Depression medicines target the amygdala because the amygdala is the integrated center for emotions and an emotional behavior. (DeRubeis, R. J., Siegle, G. J., & Hollon, S. D. 2008). Monoamine Oxidase Inhibitors MAOI’s were the first discovered anti-depressant medicine in the 1950’s, and they were originally used to treat symptoms of tuberculosis.......

Words: 1612 - Pages: 7

Premium Essay

Merck, the Fda, and the Vioxx Recall

...2004 over 139,000 people in the United States has had a heart attack or stroke as a result of taking Vioxx about 55,000 of them died. When a business is ranked on being highly successful they are mostly being ranked on profit not the amount of people they helped or cured. The pharmaceutical giant Merck that manufactured Vioxx was ranked number three of the world’s top pharmaceutical companies with sales of $30.78 billion dollars and profits of $7.8 billion. In the eight-page letter, the FDA says Merck engaged "in a promotional campaign for Vioxx that minimizes the potentially serious cardiovascular findings that were observed" in a clinical trial comparing Vioxx to naproxen, a less-expensive painkiller. "Your promotional campaign discounts the fact" that in the trial, "patients on Vioxx were observed to have a four to five-fold increase" in heart attacks, compared with patients on naproxen, the letter said (Martinez, 2004) After re-analyzing the relevant data, including those from Merck, FDA Scientist Dr David Graham estimated in early 2005 that "between 89,000 and 139,000 people had been seriously affected by the drug (Vioxx) ( Jack, 2005)." Merck now faces costly lawsuits, angry investors and falling profits ( Simmons...

Words: 1129 - Pages: 5